Equillium, Inc (EQ)

Etorro trading 970x250
Equillium, Inc (EQ) Logo

About Equillium, Inc

Equillium, Inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in La Jolla, California. Address: 2223 Avenida De La Playa, La Jolla, CA, United States, 92037

Equillium, Inc News and around…

Latest news about Equillium, Inc (EQ) common stock and company :

Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting
18 Oct, 2021 FinancialContent

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that two abstracts were accepted for presentation at the virtual 2021 American Society of Nephrology (ASN) Annual Meeting to be held November 4-7, 2021.

Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021
30 Sep, 2021 FinancialContent

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that three abstracts were accepted for presentation at ACR Convergence, the annual meeting of the American College of Rheumatology. The meeting, the world’s premier virtual rheumatology experience, will take place online November 3 - 10.

Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
22 Sep, 2021 FinancialContent

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will participate in a fireside chat presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference, taking place September 27 – 30, 2021.

Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2021
15 Sep, 2021 FinancialContent

Upgrades For Alcoa Corp (NYSE:AA), Argus Research upgraded the previous rating of Hold to Buy. Alcoa earned $1.49 in the ...

Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
08 Sep, 2021 FinancialContent

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place September 13 – 15, 2021. The virtual on-demand presentation will be available as of Monday, September 13, 2021, at 7:00 am ET.

60 Biggest Movers From Yesterday
24 Aug, 2021 FinancialContent

Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be ...

Equillium's Itolizumab Reduces Urine Protein In Lupus Patients
12 Aug, 2021 FinancialContent

Equillium Inc(NASDAQ: EQ)announced additional datafrom the Type A portion of the EQUALISE Phase 1b study of ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
11 Aug, 2021 FinancialContent

Gainers Hims & Hers Health (NYSE:HIMS) shares moved upwards by 12.53% to $8.44 during Wednesday's after-market session. This ...

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis
11 Aug, 2021 FinancialContent

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced additional data from the EQUALISE Type A portion of the study in systemic lupus erythematosus (SLE) patients. The exploratory data set shows that patients without a diagnosis of lupus nephritis (LN) but with elevated urine protein/creatine ratio (UPCR) >200 mg/g (N=6, baseline geometric mean 378 mg/g)1 experienced a mean decrease from baseline in UPCR of 33% and 42% at Days 29 and 57 respectively, following subcutaneous doses of itolizumab on Days 1 and 15. Notably, one subject who had baseline UPCR of 1,505 mg/g declined to 974 mg/g at Day 29 and 857 mg/g by Day 57. Additionally, patients with elevated albumin/creatinine ratio (ACR) >30 mg/g (N=4, baseline geometric mean 97 mg/g)1 experienced a mean decrease from baseline in ACR of 22% and 53% at Days 29 and 57 respectively.

Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update
10 Aug, 2021 FinancialContent

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced financial results for the second quarter 2021, and provided an update on its clinical programs.

What You Need To Know About Equillium, Inc.'s (NASDAQ:EQ) Investor Composition
06 Aug, 2021 Yahoo! Finance

The big shareholder groups in Equillium, Inc. ( NASDAQ:EQ ) have power over the company. Large companies usually have...

Equillium to Present at the BTIG Virtual Biotechnology Conference
05 Aug, 2021 FinancialContent

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the BTIG Virtual Biotechnology Conference, taking place August 9 & 10, 2021.

Analysts Anticipate FDM To Hit $74
29 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $74.44 per unit.

Equillium's Single Phase 3 Study In aGVHD To Support US Filing Of Itolizumab
13 Jul, 2021 FinancialContent

Equillium Inc(NASDAQ: EQ) completed an End-of-Phase 1 meeting with the FDA,confirming to advance itolizumabinto a ...

The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
13 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Monday's After-Market Session
12 Jul, 2021 FinancialContent

Gainers SCWorx (NASDAQ:WORX) shares rose 27.06% to $3.38 during Monday's after-market session. Today's trading volume for this ...

Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA
12 Jul, 2021 FinancialContent
Implied FDM Analyst Target Price: $74
24 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Dow Jones Select MicroCap Index Fund ETF (FDM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $74.36 per unit.

64 Biggest Movers From Friday
14 Jun, 2021 FinancialContent

Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per ...

12 Health Care Stocks Moving In Friday's Intraday Session
11 Jun, 2021 FinancialContent

Gainers Novan (NASDAQ:NOVN) stock rose 71.04% to $15.46 during Friday's regular session. As of 12:30 EST, ...

Equillium's Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease Patients
11 Jun, 2021 FinancialContent

Equillium Inc(NASDAQ: EQ) hasannounced positive topline datafrom the Phase 1b EQUATE study evaluating itolizumab in ...

Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease
11 Jun, 2021 FinancialContent
Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry
10 Jun, 2021 FinancialContent

Whole blood and proteomic stabilized blood assay used to elicit clinical pharmacodynamic CD6 biomarker in autoimmune diseases

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
09 Jun, 2021 FinancialContent

Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 248.41% to $7.7 during Wednesday's pre-market session. The market ...

Equillium to Present at the JMP Securities Life Sciences Conference
09 Jun, 2021 FinancialContent
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
07 Jun, 2021 FinancialContent

Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical ...

Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases
07 Jun, 2021 FinancialContent
Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June
03 Jun, 2021 FinancialContent
Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11
03 Jun, 2021 Yahoo! Finance

Presentation and conference call will include topline data from all cohorts The risk-benefit profile observed supports advancing development of itolizumab in first-line therapy LA JOLLA, Calif.., June 03, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will host a conference call on Friday, June 11, 2021, at 8:00 am ET, following an oral presentation

Equillium to Present at the Jefferies Virtual Healthcare Conference
26 May, 2021 FinancialContent

Equillium, Inc (EQ) is a NASDAQ Common Stock listed in , ,

970x250